NOhep Village

NOhep Village

Bringing together civil society organisations and the scientific community to advocate for the elimination of viral hepatitis

This year the World Hepatitis Alliance will bring together a NOhep Village at the Global Hepatitis Summit on 14 – 17 June 2018 in Toronto. The NOhep Village will be an interactive and dynamic space to foster networking and collaborative learning between civil society organisations, patients and the scientific community.

The scientific community and civil society are united by a common goal, to achieve the elimination of viral hepatitis by 2030. Both have a different but essential set of skills and expertise and it is therefore crucial to work collaboratively in order to achieve this shared objective. Yet, patient groups often lack scientific understanding, while the scientific community is not always aware of the experiences of people living with viral hepatitis and the role they could play in achieving elimination. The NOhep Village will be a unique opportunity to start bridging this gap.


The ISVHLD Global Hepatitis Summit is an international liver meeting taking place on 14 – 17 June 2018 in Toronto, Canada. The event will be attended by over 2,000 top clinicians and researchers from around the world for a high quality program of sessions in basic, clinical, and public health science of viral hepatitis and liver disease. In addition to this, the upcoming Summit will include a new and important focus on global public health, to which the NOhep Village will contribute.


The NOhep Village will include civil society exhibition stands, short talks and panel discussions, videos and networking areas. Saturday 16 June will be the NOhep Village Advocacy Day, during which the Village will be open to the public for an exciting programme of events. This will serve as a vibrant area where both regional and global communities gather to meet, share and learn from one another.

World Hepatitis Alliance staff members will be in the Village to answer any questions, and with 256 members in 87 countries they are uniquely placed to link the scientific community with civil society organisations from across the globe. 


We are looking to partner with civil society organisations who wish to showcase their activities by exhibiting their work in the NOhep Village. There are a number of exhibition spaces available, 6 of which will be funded.

Exhibiting in the NOhep Village is an excellent opportunity to network with other organisations and key influencers, to gain exposure to sponsors and to harness the learning opportunities available at a large global event. The Village will be in the main event exhibition hall so you can guarantee that your work is seen by a global audience.

In addition to the opportunity to exhibit, selected NGOs will also get the chance to present as part of the NOhep Village programme.

Please read the exhibitor guidelines and selection criteria carefully before submitting your proposal using the exhibitor application form. Please note, all applications will be considered for a funded space.


  • Submissions open: Wednesday 17 January 2018
  • Submissions close: Friday 2 March 2018
  • Notifications sent: week commencing 12 March 2018

NOhep Village Objectives

The overall objective of the NOhep Village is to foster networking and collaborative learning between patient groups and the scientific community to create a greater and better connected community of advocates. The Village also aims to:

  • Build a productive learning and networking environment that harnesses the expertise of civil society organisations and the scientific community and promote collaboration and partnership between those communities
  • Show the important role that both groups have to play in advocating for the elimination of viral hepatitis
  • Showcase how only by working together elimination can be a reality
  • Harness the power of people living with viral hepatitis
  • Create a vibrant and engaging experience for conference delegates and the public living in Toronto
  • Celebrate the successes and discuss the challenges of the viral hepatitis response, both at a country and global level


If you have any questions please contact